Table 3.

Top canonical pathways

Patient 1		Patient 2		Patient 3		Patient 4		Patient 5
Protein	P value	Protein	P value	Protein	P value	Protein	P value	Protein	P value
LXR/RXR activation	2.04E−12	Glycolysis I	2.06E−07	LXR/RXR activation	3.14E−15	LXR/RXR activation	3.11E−18	LXR/RXR activation	2.92E−19
Glycolysis I	3.13E−11	LXR/RXR activation	1.02E−04	FXR/RXR activation	1.69E−13	Acute phase response signaling	5.67E−16	FXR/RXR activation	2.88E−17
FXR/RXR activation	8.01E−10	Clathrin-mediated endocytosis signaling	6.79E−04	Acute phase response signaling	2.32E−09	FXR/RXR activation	7.25E−15	Acute phase response signaling	1.53E−15
Gluconeogenesis I	1.61E−09	Gluconeogenesis I	1.25E−03	Atherosclerosis signaling	2.97E−09	Glycolysis I	1.24E−11	Clathrin-mediated endocytosis signaling	5.04E−09
Acute phase response signaling	2.36E−09	FXR/RXR activation	2.08E−03	Clathrin-mediated endocytosis signaling	1.06E−08	Atherosclerosis signaling	3.63E−09	Glycolysis I	1.01E−08